In The Spotlight
- 12 September 2017 - 14 September 2017
- Malmömassan – Malmö Convention Center Mässgatan 6 215 32
- Malmö – Sweden
- 05 May 2017 - 07 May 2017
- Bologna Fair Centre
- Bologna, Italy
- 07 November 2017 - 10 November 2017
- Shanghai New International Exhibition Centre (SNIEC)
- Shanghai ,China
- 15 May 2017 - 18 May 2017
- National Exhibition and Convention Center
- Shanghai, China
- 28 June 2017 - 30 June 2017
- Tokyo Big Sight
- Tokyo, Japan
Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases announced a research and development (R&D) agreement with Galapagos NV.
Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform announced that the U.S. FDA has completed its initial review of the ropinirole implant Investigational New Drug Application (IND) and has requested that Titan hold the initiation of the clinical study pending submission of the requested information and the agency's 30-day review.
Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody.
Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).
LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema.
Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)’s 1st Scientific Meeting on “Vaccines Against Emerging Infections - A Global Insurance” in Paris, France.
Charles River Laboratories International, Inc. , a leading early-stage contract research organization announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease.
Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.
Johnson Matthey, a global specialty chemicals company and provider of advanced process technologies, and Rennovia Inc., a privately held company that develops novel catalysts and processes for the cost advantaged production of chemical products from renewable feedstocks.
Mettler-Toledo, a market leader in product inspection technology, will present a comprehensive range of solutions and upgradesat interpack 2017 (www.mt.com/interpack17) for both the food and pharmaceutical sectors, as well as providing a wealth of technical knowledge via its experts at the stand.
Life science researchers working across many applications can now benefit from the first-ever web-based pipetting application, developed to enable seamless connectivity with electronic pipettes for optimized performance and safe, efficient and rapid sharing of protocols.
Fluorescing UV inks offer a number of advantages, including high print quality, improved durability and enhanced productivity.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers. If this data were liberated to the masses, we would venture into a world of endless possibilities where the search for new cures and treatments could be accelerated.
Ferring Pharmaceuticals announced an agreement with Apricus Biosciences, Inc, granting Ferring global assets and rights, excluding the U.S., related to Apricus’ Vitaros.
Thermo Fisher Scientific Inc, the world leader in serving science announced that it has acquired Core Informatics, which provides a leading cloud-based platform supporting scientific data management.
ICON plc a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US FDA to validate three PRO instruments that will measure clinical endpoints in antibacterial drug trials.
Regenerative and cell-based therapies have only recently begun to deliver on the promise they have portended for years, creating opportunities to positively impact patient outcomes and professional success.
Type 2 diabetes awareness is rising in the United States. Public and private health leaders are now offering screenings and patient education sites that discuss “prediabetes,” to detect and treat the disease in its earliest stages.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.
TraceLink Inc, the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace.
TV spot showcases the science behind the ultimate breathability and comfort of DAILIES TOTAL1® contact lenses
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc announced that the U.S. FDA granted approval for Basaglar 100 units/mL. BASAGLAR is a long-acting insulin with an identical amino acid sequence to Lantus®, another U-100 insulin glargine.